Mallinckrodt CEO signs new employment agreement with $1.2M base, $12M inducement awards, contingent on Endo merger

Keenova Therapeutics plc

CEO Sigurdur Olafsson's new agreement is effective upon completion of the Endo merger; term ends Jan 1, 2027.
Base salary of $1.2M; annual bonus target 200% of base (max 400%) post-merger.
Cash inducement award of $6M lump sum payable Jan 2027; equity inducement RSUs of $6M vesting same date.
Severance upon termination without cause: lump sum of 2.5x (base + target bonus), prorated bonus, vesting of inducements, 30 months COBRA.
12-month non-compete/non-solicit restrictions post-termination, with exceptions if termination is after Expiration Date or certain conditions.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.